Valneva (INRLF) 3.7400 $INRLF Cholera Vaccines
Post# of 273242
Posted On: 09/15/2016 7:08:50 AM
Valneva (INRLF) 3.7400 $INRLF
Cholera Vaccines Market Size To Reach $1.25 Billion By 2024: Grand View Research, Inc.
GlobeNewswire - Tue Sep 06, 4:00AM CDT
Global cholera vaccines market is expected to reach over USD 1.25 billion by 2024, according to a new report by Grand View Research, Inc. The presence of wide range of promising vaccine candidates in the pipeline is anticipated to accentuate growth of the cholera vaccines market over the forecast period. In July 2016, Valneva SE has announced completion of phase II clinical trial for Clostridium difficile vaccine candidate.
VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccines Sandovac(R) and Fluad(R) in Austria
GlobeNewswire - Thu Aug 25, 12:13AM CDT
Valneva SE ("Valneva" or "the Company"
, a leading pure play vaccine company, today announced the signing of an agreement with Seqirus, the second largest flu company in the world, for the marketing & distribution of Seqirus' seasonal flu vaccines Sandovac and Fluad in the Austrian market.
VALNEVA Evaluating Development of Zika Vaccine as Virus Spreads Through the Americas
GlobeNewswire - Tue Feb 02, 10:55AM CST
Valneva SE ("Valneva" or "the Company" , a leading pure play vaccine company, announces today that it is evaluating the development of a Zika vaccine as the virus is spreading rapidly through the Americas.
Streptococcus Pneumoniae Infection Therapeutic Developments Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/klpqfj/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Streptococcus Pneumoniae Infection Overview - Therapeutics Development - Pipeline Products for Streptococcus Pneumoniae Infection - Overview - Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis - Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Streptococcus Pneumoniae Infection - Products under Development by Companies - Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development - Abera Bioscience AB - Allergan Plc - Alvogen Korea - Arsanis Biosciences GmbH - AstraZeneca Plc - Beijing Minhai Biotechnology Co., Ltd - ContraFect Corporation - Daiichi Sankyo Company, Limited - Eurocine Vaccines AB - FluGen, Inc. - GlaxoSmithKline Plc - ImmunoBiology Limited - Lascco SA - Liquidia Technologies, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Mucosis B.V. - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Valneva SE - Vaxxilon AG - Virometix AG - Walvax Biotechnology Co., Ltd. - Wellstat Vaccines, LLC - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/kl...eptococcus
AGN: 244.81 (+4.71), MRK: 61.35 (-0.46), AZN: 33.10 (+0.36), GSK: 43.15 (+0.64), SVA: 5.82 (unch)
Valneva SE Product Pipeline Review Market Analysis Report 2015: Radiant Insights, Inc
M2 - Wed Jan 20, 5:44AM CST
Summary
Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America
M2 - Wed Jan 20, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/9xxd67/biopharmaceutical) has announced the addition of the "Biopharmaceutical Market: By Source, By End Users (Hospitals & Others) - Forecast (2015 - 2020)" report to their offering. Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs. The market for biopharmaceuticals is classified into three categories based on: - Source - Type of products - Application areas Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market. Companies Mentioned: - Johnson & Johnson Private Limited - Roche Holding AG - Abbott Laboratories - Bristol-Myers Squibb - Novartis International AG - Genentech Inc - UCB - Merck Serono - Amgen - Eli Lilly & Co - Biogen Idec - Merck KGaA - ?lan Corporation - BioMarin Pharmaceutical Inc - AbbVie Inc - Invion Limited - AdAlta Pty Ltd - Admedus Ltd - Biota Pharmaceuticals Inc - Novozymes - Baxter International - APEIRON Biologics AG - Octapharma AG - Valneva SE - Genzyme - Mallinckrodt Pharmaceuticals - TM3 Therapeutics Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Market Strategic Analysis 6. Market - By Source 7. Market - By Products 8. Market - By Manufacturing Process 9. Market - By Application 10. Market - By End Users 11. Market - Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/9x...maceutical
ABT: 40.81 (+0.17), BIIB: 299.79 (+2.38), BMRN: 95.30 (+1.42), BOTA: 1.55 (-0.04), AMGN: 170.14 (+0.84), LLY: 78.29 (-0.19), BMY: 55.23 (-0.37), JNJ: 117.86 (+0.25), BAX: 45.43 (+0.05), MRK: 61.35 (-0.46), ABBV: 63.34 (unch), NVS: 79.11 (-0.01)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, Technologies & Forecasts Report H2 2015
M2 - Tue Dec 08, 3:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/svhgsp/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015" report to their offering. The report Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015', provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics Companies Mentioned Include: Absynth Biologics Limited Actelion Ltd AIMM Therapeutics B.V. Akthelia pharmaceuticals ehf Angothera GmbH AvidBiotics Corp. C3 Jian, Inc Daiichi Sankyo Company, Limited Valevia UK Limited Valneva SE For more information visit http://www.researchandmarkets.com/research/sv...lostridium
VALNEVA Announces U.S. Distribution and Marketing Services Agreements with VaxServe for Japanese Encephalitis Vaccine IXIARO(R)
GlobeNewswire - Mon Nov 09, 11:22AM CST
Valneva SE ("Valneva" , a leading pure-play vaccine company, announced today that its fully owned US subsidiary Intercell USA, Inc. has entered into distribution and marketing services agreements with VaxServe, Inc. ("VaxServe" , a Sanofi Pasteur company, for Valneva's Japanese encephalitis (JE) vaccine IXIARO in the United States (U.S.). This collaboration is part of Valneva's strategy to commercialize IXIARO through a combination of its own sales & marketing infrastructure and distribution agreements with established local partners at favorable terms.
Arch Therapeutics Appoints James Sulat to Board of Directors
Marketwired - Thu Aug 20, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)" , has appointed James Sulat to its Board of Directors as an independent member, effective August 19, 2015. This brings the total number of Board members to three.
AMAG: 23.97 (+0.62), MNTA: 11.69 (+0.17)
VALNEVA and PaxVax Enter into Marketing and Distribution Agreement
GlobeNewswire - Thu Jul 23, 12:42AM CDT
Valneva SE ("Valneva" , a leading pure-play vaccine biotech company and PaxVax, Inc. ("PaxVax" , a fully integrated specialty vaccine company focused on travel, announced today that they have entered into a marketing and distribution agreement for their respective travel vaccines, DUKORAL and Vivotif.
VALNEVA announces successful outcome of its AGM and renewal of the term of office of its management board members
GlobeNewswire - Fri Jun 26, 12:32AM CDT
Valneva SE ("Valneva" , a leading pure-play vaccines biotech company announced today that all the resolutions supported by the management board (excluding one resolution which lacked quorum) have been adopted by the shareholders at its Annual General Meeting (AGM) held in Paris on June 25, 2015.
Cholera Vaccines Market Size To Reach $1.25 Billion By 2024: Grand View Research, Inc.
GlobeNewswire - Tue Sep 06, 4:00AM CDT
Global cholera vaccines market is expected to reach over USD 1.25 billion by 2024, according to a new report by Grand View Research, Inc. The presence of wide range of promising vaccine candidates in the pipeline is anticipated to accentuate growth of the cholera vaccines market over the forecast period. In July 2016, Valneva SE has announced completion of phase II clinical trial for Clostridium difficile vaccine candidate.
VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccines Sandovac(R) and Fluad(R) in Austria
GlobeNewswire - Thu Aug 25, 12:13AM CDT
Valneva SE ("Valneva" or "the Company"
, a leading pure play vaccine company, today announced the signing of an agreement with Seqirus, the second largest flu company in the world, for the marketing & distribution of Seqirus' seasonal flu vaccines Sandovac and Fluad in the Austrian market. VALNEVA Evaluating Development of Zika Vaccine as Virus Spreads Through the Americas
GlobeNewswire - Tue Feb 02, 10:55AM CST
Valneva SE ("Valneva" or "the Company"
, a leading pure play vaccine company, announces today that it is evaluating the development of a Zika vaccine as the virus is spreading rapidly through the Americas. Streptococcus Pneumoniae Infection Therapeutic Developments Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/klpqfj/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Streptococcus Pneumoniae Infection Overview - Therapeutics Development - Pipeline Products for Streptococcus Pneumoniae Infection - Overview - Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis - Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Streptococcus Pneumoniae Infection - Products under Development by Companies - Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development - Abera Bioscience AB - Allergan Plc - Alvogen Korea - Arsanis Biosciences GmbH - AstraZeneca Plc - Beijing Minhai Biotechnology Co., Ltd - ContraFect Corporation - Daiichi Sankyo Company, Limited - Eurocine Vaccines AB - FluGen, Inc. - GlaxoSmithKline Plc - ImmunoBiology Limited - Lascco SA - Liquidia Technologies, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Mucosis B.V. - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Valneva SE - Vaxxilon AG - Virometix AG - Walvax Biotechnology Co., Ltd. - Wellstat Vaccines, LLC - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/kl...eptococcus
AGN: 244.81 (+4.71), MRK: 61.35 (-0.46), AZN: 33.10 (+0.36), GSK: 43.15 (+0.64), SVA: 5.82 (unch)
Valneva SE Product Pipeline Review Market Analysis Report 2015: Radiant Insights, Inc
M2 - Wed Jan 20, 5:44AM CST
Summary
Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America
M2 - Wed Jan 20, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/9xxd67/biopharmaceutical) has announced the addition of the "Biopharmaceutical Market: By Source, By End Users (Hospitals & Others) - Forecast (2015 - 2020)" report to their offering. Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs. The market for biopharmaceuticals is classified into three categories based on: - Source - Type of products - Application areas Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market. Companies Mentioned: - Johnson & Johnson Private Limited - Roche Holding AG - Abbott Laboratories - Bristol-Myers Squibb - Novartis International AG - Genentech Inc - UCB - Merck Serono - Amgen - Eli Lilly & Co - Biogen Idec - Merck KGaA - ?lan Corporation - BioMarin Pharmaceutical Inc - AbbVie Inc - Invion Limited - AdAlta Pty Ltd - Admedus Ltd - Biota Pharmaceuticals Inc - Novozymes - Baxter International - APEIRON Biologics AG - Octapharma AG - Valneva SE - Genzyme - Mallinckrodt Pharmaceuticals - TM3 Therapeutics Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Market Strategic Analysis 6. Market - By Source 7. Market - By Products 8. Market - By Manufacturing Process 9. Market - By Application 10. Market - By End Users 11. Market - Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/9x...maceutical
ABT: 40.81 (+0.17), BIIB: 299.79 (+2.38), BMRN: 95.30 (+1.42), BOTA: 1.55 (-0.04), AMGN: 170.14 (+0.84), LLY: 78.29 (-0.19), BMY: 55.23 (-0.37), JNJ: 117.86 (+0.25), BAX: 45.43 (+0.05), MRK: 61.35 (-0.46), ABBV: 63.34 (unch), NVS: 79.11 (-0.01)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, Technologies & Forecasts Report H2 2015
M2 - Tue Dec 08, 3:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/svhgsp/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015" report to their offering. The report Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015', provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics Companies Mentioned Include: Absynth Biologics Limited Actelion Ltd AIMM Therapeutics B.V. Akthelia pharmaceuticals ehf Angothera GmbH AvidBiotics Corp. C3 Jian, Inc Daiichi Sankyo Company, Limited Valevia UK Limited Valneva SE For more information visit http://www.researchandmarkets.com/research/sv...lostridium
VALNEVA Announces U.S. Distribution and Marketing Services Agreements with VaxServe for Japanese Encephalitis Vaccine IXIARO(R)
GlobeNewswire - Mon Nov 09, 11:22AM CST
Valneva SE ("Valneva"
, a leading pure-play vaccine company, announced today that its fully owned US subsidiary Intercell USA, Inc. has entered into distribution and marketing services agreements with VaxServe, Inc. ("VaxServe" , a Sanofi Pasteur company, for Valneva's Japanese encephalitis (JE) vaccine IXIARO in the United States (U.S.). This collaboration is part of Valneva's strategy to commercialize IXIARO through a combination of its own sales & marketing infrastructure and distribution agreements with established local partners at favorable terms. Arch Therapeutics Appoints James Sulat to Board of Directors
Marketwired - Thu Aug 20, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)" , has appointed James Sulat to its Board of Directors as an independent member, effective August 19, 2015. This brings the total number of Board members to three. AMAG: 23.97 (+0.62), MNTA: 11.69 (+0.17)
VALNEVA and PaxVax Enter into Marketing and Distribution Agreement
GlobeNewswire - Thu Jul 23, 12:42AM CDT
Valneva SE ("Valneva"
, a leading pure-play vaccine biotech company and PaxVax, Inc. ("PaxVax" , a fully integrated specialty vaccine company focused on travel, announced today that they have entered into a marketing and distribution agreement for their respective travel vaccines, DUKORAL and Vivotif. VALNEVA announces successful outcome of its AGM and renewal of the term of office of its management board members
GlobeNewswire - Fri Jun 26, 12:32AM CDT
Valneva SE ("Valneva"
, a leading pure-play vaccines biotech company announced today that all the resolutions supported by the management board (excluding one resolution which lacked quorum) have been adopted by the shareholders at its Annual General Meeting (AGM) held in Paris on June 25, 2015. 
(0)
(0)Scroll down for more posts ▼